Hari Kumar served at Roche before joining Eisai Ltd as European Marketing Director. He then returned to Roche as Global Head of Transplant Immunosuppressives. He moved to Amira Pharmaceuticals Inc. in 2007 as Chief Business Officer. In 2013 Dr. Kumar became Chief Executive Officer of Adheron Therapeutics Inc. In his career, Dr. Kumar oversaw the launch of the immunosuppressive, CellCept®, the Alzheimer’s drug, Aricept® and the gastric ulcer drug, Aciphex®. His experience in almost all aspects of the pharmaceutical industry has given him a unique understanding of what makes a successful pharmaceutical business. At Amira, Dr. Kumar led the process that resulted in its acquisition by Bristol Myers Squibb in 2011. He also navigated the acquisition of Adheron Therapeutics by Roche, in his roles both as CEO and Board member. These transactions have delivered over a billion dollars in returns to investors.

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.